BC Week In Review | Jan 18, 2010
Clinical News

CXB722: Phase I data

In a Phase I trial in 24 healthy volunteers, CXB722 significantly reduced several neuroendocrine biomarkers that typically rise in response to acute psychosocial stress, including plasma cortisol, salivary cortisol and plasma adrenocorticotropic hormone, while subjects...
Items per page:
1 - 1 of 1